1. Introduction {#sec0001}
===============

Oral delivery is regarded as the most desirable route of administration, given its non-invasiveness and high patient acceptability [@bib0001]. Among the various types of oral formulations, solid dosage forms like capsules and tablets are preferred due to the dosing convenience, high physicochemical stability, and cost-effectiveness [@bib0002], [@bib0003]. However, the large size of solid formulations is challenging for patients with dysphagia -- often the elderly and children -- to swallow, which in turn promoted the development of novel oral formulations, including sprinkle formulations [@bib0001], [@bib0004], [@bib0005], [@bib0006].

Sprinkle formulations are drug-containing pellets or granules that can be mixed with soft food before administration ([Fig. 1](#fig0001){ref-type="fig"}). These formulations provide almost the same dosing flexibility and ease of ingestion as liquid formulations when sprinkled on liquid or semi-solid vehicles, such as applesauce, pudding or yogurt [@bib0002], [@bib0006]. The food taken together with the drug can also mask the unpleasant taste and smell of the drug substance, which potentially improves patient compliance [@bib0007]. Moreover, sprinkle formulations are available in tablet or capsule formulations for the convenience of handling and can be readily crushed or opened before being sprinkled on food, respectively [@bib0008]. Due to their solid state, sprinkle formulations guarantee the higher stability of loaded drugs than liquid formulations during storage [@bib0009].Fig. 1General administration methods for the sprinkle drug products in various dosage forms including tablets, powder, granules, immediate-release (IR) capsules, extended-release (ER) capsules, delayed-release (DR) capsules, and multiparticulate drug delivery system (MDDS).Fig 1

Since the first product was approved by the US Food and Drug Administration (FDA) in the early 1940s, sixty-five original sprinkle formulations have been marketed in the US ([Fig. 2](#fig0002){ref-type="fig"}). The commercially available sprinkle formulations can be classified into seven formulation types, consisting of tablets, powder, granules, immediate-release (IR) capsules, extended-release (ER) capsules, delayed-release (DR) capsules, and multiparticulate drug delivery system (MDDS). [Table 1](#tbl0001){ref-type="table"}, [Table 2](#tbl0002){ref-type="table"}, [Table 3](#tbl0003){ref-type="table"}, [Table 4](#tbl0004){ref-type="table"}, [Table 5](#tbl0005){ref-type="table"}, [Table 6](#tbl0006){ref-type="table"}, [Table 7](#tbl0007){ref-type="table"} show the formulation types arranged by the date of approval in the US. This review aims to provide the information of each sprinkle product regarding its drug substance, pharmaceutical ingredients, storage condition, and administration method. In addition, FDA guidance articles related to sprinkle formulations were introduced for the future development of this formulation.Fig. 2The number of approved New Drug Applications (NDAs) for sprinkle drug products since 1941. A total of sixty-five original sprinkle products are available on the US pharmaceutical market.Fig 2Table 1Commercially available sprinkle products -- tablets.Table 1Brand/Generic namesIndicationsStrength/StorageExcipientsManipulationCompanyInitial US approvalDoryx^Ⓡ^/doxycycline hyclateTreatment and prevention of bacterial infections50 and 200 mg\
Store at 20 to 25 °C in a tight and light-resistant container.Lactose monohydrate; MCC; SLS; Sodium chloride; Talc; Anhydrous lactose; Corn starch; Crospovidone; Magnesium stearate; Cellulosic polymer coatingCarefully crush the tablet and must not be crush or damage of delayed-release pellets. Sprinkle the tablet fragments on a spoonful of applesauce.Mylan1967Jadenu^Ⓡ^/deferasiroxTreatment of chronic iron overload90, 180, and 360 mg\
Store at 20 to 25 °C and protect from moisture.MCC; Crospovidone; Povidone K30; Magnesium stearate; Colloidal silicon dioxide; Poloxamer 188Carefully crush the tablet and sprinkle the tablet fragments on applesauce.Novartis2005Kuvan^Ⓡ^/sapropterin dihydrochlorideTetrahydrobiopterin-responsive phenylketonuria100 mg\
Store below 25 °C and protect from moisture.Ascorbic acid; Crospovidone;Dibasic calcium phosphate; [D]{.smallcaps}-mannitol; Riboflavin; Sodium stearyl fumarateDissolve powder in 120 to 240 mL of water or apple juice, or in a small quantity of soft foods such as applesauce or pudding.\
Consume within 30 min of dissolution.\
For infants weighing less than 10 kg, dissolve powder in 5 mL of water or apple juice and administer this solution orally using a syringe.BioMarin Pharmaceutical2007Xarelto^Ⓡ^/rivaroxabanPrevention and treatment of thromboembolism10, 15, and 20 mg\
Store at 25 °C or room temperature.Croscarmellose sodium; HPMC; Lactose monohydrate; Magnesium stearate; MCC; SLSCarefully crush the tablet and sprinkle the tablet fragments on applesauce.Janssen2011Onfi^Ⓡ^/clobazamTreatment of seizures10 and 20 mg\
Store at 20 to 25 °C.Corn starch; Lactose monohydrate; Magnesium stearate; SD; TalcCarefully crush the tablet and sprinkle the tablet fragments on applesauce.Lundbeck2011Eliquis^Ⓡ^/apixabanPrevention and treatment of thromboembolism2.5 and 5 mg\
Store at 20 to 25 °C.Anhydrous lactose; MCC; Croscarmellose sodium; SLS; Magnesium stearateCarefully crush the tablet and sprinkle the tablet fragments on water, 5% dextrose in water, apple juice, or applesauce.Bristol-Myers Squibb2012Savaysa^Ⓡ^/edoxabanPrevention and treatment of thromboembolism15, 30, and 60 mg\
Store at 20 to 25 °C.Mannitol; Pre-gelatinized starch; Crospovidone; HPC; Magnesium stearate; Talc; Carnauba waxCarefully crush the tablet and sprinkle the tablet fragments on applesauce.Daiichi Sankyo2015Emflaza™/deflazacortTreatment of Duchenne muscular dystrophy6, 18, 30, and 36 mg\
Store at 20 to 25 °C.Colloidal silicon dioxide; Lactose monohydrate; Magnesium stearate; Pre-gelatinized corn starch;Carefully crush the tablet and sprinkle the tablet fragments on applesauce.PTC Therapeutics2017Trulance^Ⓡ^/plecanatideTreatment of chronic idiopathic constipation3 mg\
Store at 20 to 25 °C in the original bottle and protect from moisture.Magnesium stearate; MCCCarefully crush the tablet and sprinkle the tablet fragments on applesauce.Synergy Pharmaceuticals2017Table 2Commercially available sprinkle products -- powder.Table 2Brand/Generic NameIndicationStrength/StorageExcipientsManipulationCompanyInitial US ApprovalViread^Ⓡ^/tenofovir disoproxil fumarateTreatment of HIV-1 infection and chronic hepatitis B40 mg per 1 g powder\
Store at 25  °C in the original container.Mannitol; HPC; EC; SDSprinkle powder on soft food such as applesauce, baby food, or yogurt.Gilead Sciences2001Reyataz^Ⓡ^/atazanavirTreatment of HIV-1 infection50 mg per packet\
Store at 25  °C.Aspartame; SucroseMix powder with soft food (applesauce or yogurt) or liquid (milk, infant formula, or water).\
If the vehicle is water, the patient must eat food immediately after taking Reyataz^Ⓡ^.\
For infants less than 6 months, the powder should be mixed with infant formula and administered using an oral syringe.Bristol-Myers Squibb2003Fosrenol^Ⓡ^/lanthanum carbonateReduction of serum\
phosphate in patients with end-stage renal disease750 and 1000 mg\
Store at 25  °C and protect from moisture.Colloidal silicon dioxide; Dextrates; Magnesium stearateSprinkle powder on a small amount of applesauce or other similar food and consume immediately.Shire2004Kuvan^Ⓡ^/sapropterin dihydrochlorideTetrahydrobiopterin-responsive phenylketonuria100 and 500 mg\
Store below 25  °C and protect from moisture.Ascorbic acid; [d]{.smallcaps}-mannitol; Potassium citrate; SucraloseDissolve powder in 120 to 240 mL of water or apple juice, or in a small quantity of soft foods such as applesauce or pudding.\
Consume within 30 min of dissolution.\
For infants weighing less than 10 kg, dissolve the powder in 5 mL of water or apple juice and administer this solution orally using a syringe.BioMarin Pharmaceutical2007Table 3Commercially available sprinkle products -- granules.Table 3Brand/Generic namesIndicationStrength/StorageExcipientsManipulationCompanyInitial US approvalSingulair^Ⓡ^/montelukast sodiumProphylaxis and chronic treatment of asthma, acute prevention of exercise-induced bronchoconstriction, and alleviation of allergic rhinitis4 mg\
Store at 15 to 30  °C in the original package and protect from moisture and light.Mannitol; HPC; Magnesium stearateDissolve granules in a teaspoonful of baby formula or breast milk, or mix with a spoonful of soft foods, only applesauce, carrots, rice, or ice cream.\
Do not dissolve granules in any liquid other than baby formula or breast milk for administration.Merck1998Protonix^Ⓡ^/pantoprazole sodiumTreatment of erosive esophagitis and pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)40 mg\
Store at 20 to 25  °C.Crospovidone; HPMC; Methacrylic acid copolymer; MCC; Polysorbate 80; Povidone; Sodium carbonate; SLS; Talc; Titanium dioxide; Triethyl citrate; Yellow iron oxideSprinkle granules on applesauce.\
Do not use other foods.\
Do not crush or chew the granules.Pfizer2000Jadenu^Ⓡ^ Sprinkle/deferasiroxTreatment of chronic iron overload90, 180, and 360 mg\
Store at 20 to 25  °C and protect from moisture.MCC; Crospovidone; Povidone K30;Magnesium stearate; Colloidal silicon dioxide; Poloxamer 188Sprinkle granules on soft food such as yogurt or applesauce.Novartis2005Kalydeco^Ⓡ^/ivacaftorTreatment of cystic fibrosis50 and 75 mg\
Store at 20 to 25 °C.Colloidal silicon dioxide; Croscarmellose sodium; HPMC acetate-succinate; Lactose monohydrate; Magnesium stearate; Mannitol; Sucralose; SLSSprinkle granules on soft food or liquid.Vertex Pharmaceuticals2012Xuriden^Ⓡ^/uridine triacetateTreatment of hereditary orotic aciduria2 g per packet\
Store at 25  °C.EC; HPMC; PEGSprinkle granules on applesauce, pudding, or yogurt, or mix with milk or infant formula.Wellstat Therapeutics Corporation2015Vistogard^Ⓡ^/uridine triacetateEmergency treatment of overdose or severe adverse reactions of fluorouracil or capecitabine10 g per packet\
Store at 25  °C.EC; HPMC; PEGSprinkle granules on soft foods, such as applesauce, pudding, or yogurt, and ingest within 30 min.\
Do not chew the granules.Wellstat Therapeutics Corporation2015Solosec™/secnidazoleTreatment of bacterial vaginosis2 g per packet\
Store at 20 to 25  °C.Ethyl acrylate-methyl methacrylate copolymer; PEG4000; Povidone; Sugar spheres; TalcSprinkle granules on applesauce, yogurt, or pudding without chewing or crunching the granules.\
Do not try to dissolve the granules in any liquid.Lupin2017Table 4Commercially available sprinkle products -- IR capsules.Table 4Brand/Generic namesIndicationStrength/StorageExcipientsManipulationCompanyInitial US approvalChemet^Ⓡ^/succimerTreatment of lead, mercury, and arsenic poisoning100 mg\
Store at 15 to 25  °C.Povidone;Sodium starch glycolate;Starch;SucroseCarefully open the capsule and sprinkle the contents (beads) on a small amount of soft food or putting them in a spoon and following with fruit drink.Recordati Rare1991Sustiva^Ⓡ^/efavirenzTreatment of HIV-1 infection50 and 200 mg\
Store at 25  °C.Lactose monohydrate;Magnesium stearate;SLS;Sodium starch glycolateCarefully open the capsule and mix the contents with soft food, such as applesauce, grape jelly, or yogurt.\
For young infants who are not able to ingest solid foods, the contents can be administered with infant formula.Bristol-Myers Squibb1992Cystagon^Ⓡ^/cysteamine bitartrateTreatment of nephropathic cystinosis50 and 150 mg\
Store at 20 to 25  °C and protect from light and moisture.Colloidal silicon dioxide;Croscarmellose sodium;D&C yellow \#10;FD&C blue \#1;FD&C blue \#2;FD&C red \#40;Gelatin;Magnesium stearate;MCC;Pharmaceutical glaze;Pregelatinized starch;SLS;Black iron oxide;Titanium dioxideFor children under the age of six, carefully open the capsule and sprinkle the contents on food to prevent choking.Mylan1995Topamax^Ⓡ^ Sprinkle Capsules/topiramateTreatment of epilepsy and prevention of migraine15 and 25 mg\
Store at or below 25 °C and protect from moisture.Povidone;Cellulose acetate;SD\
SLS;Gelatin;Sorbitan monolaurate;Sugar spheres;Titanium dioxideCarefully open the capsule and sprinkle the contents on soft food.\
Ingest the mixture immediately without chewing.Janssen1996Celebrex^Ⓡ^/celecoxibTreatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea100 and 200 mg\
Store at 20 to 25  °C.Croscarmellose sodium;Gelatin\
Lactose monohydrate;Magnesium stearate;Povidone;SLSCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture immediately with water.GD Searle1998Colazal™/balsalazide disodiumTreatment of ulcerative colitis750 mg\
Store at 20 to 25  °C.Colloidal silicon dioxide;Magnesium stearateCarefully open the capsule and sprinkle the contents on applesauce.\
Chew or swallow the mixture immediately.Valeant Pharms2000Orfadin^Ⓡ^/nitisinoneTreatment of hereditary tyrosinemia type 12, 5, 10, and 20 mg\
Store refrigerated at 2 to 8 °C or store at room temperature up to 45 days.HPMC;Glycerol;Polysorbate 80;Sodium benzoate;Citric acid monohydrate Trisodium citrate dehydrate;Strawberry aromaCarefully open the capsule and sprinkle the contents on water, formula, or applesauce immediately before use.Swedish Orphan Biovitrum2002Tasigna^Ⓡ^/nilotinibTreatment of Philadelphia chromosome positive chronic myeloid leukemia150 and 200 mg\
Store at 25 °C.Colloidal silicon dioxide;Crospovidone;Lactose monohydrate;Magnesium stearate;Poloxamer 188Carefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture within 15 min.Novartis2007Rapaflo^Ⓡ^/silodosinTreatment of the signs and symptoms of benign prostatic hyperplasia4 and 8 mg\
Store at 25 °C and protect from light and moisture.[d]{.smallcaps}-mannitol;Magnesium stearate;Pre-gelatinized starch;SLSCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture within 5 min without chewing.Allergan2008Table 5Commercially available sprinkle products -- ER capsules.Table 5Brand/Generic namesIndicationStrength/StorageExcipientsManipulationCompanyInitial US ApprovalKadian^Ⓡ/^\
morphine sulfateManagement of severe pain10, 20, 30, 40, 50, 60, 70, 80, 100, 130, 150, and 200 mg\
Store at 25 °C and protect from light and moisture.HPMC;EC;Methacrylic acid copolymer;PEG;DEP;Talc;Corn starch;SucroseCarefully open the capsule and sprinkle the contents on applesauce.\
Do not use other foods.\
Do not chew the granules.Actavis1941Xtampza^Ⓡ^ ER/\
oxycodoneManagement of severe pain9, 13.5, 18, 27, and 36 mg\
Store at 25 °C in tight and light-resistant container.Myristic acid;Yellow beeswax;Carnauba wax;Gelucire 50/13;Magnesium stearate;Colloidal silicon dioxideCarefully open a capsule and sprinkle the contents on applesauce, pudding, yogurt, ice cream or jam.Collegium Pharmaceutical1950Aptensio XR™/\
methylphenidate hydrochlorideTreatment of ADHD10, 15, 20, 30, 40, 50, and 60 mg\
Store at 20 to 25 °C and protect from moisture.Sugar spheres;HPMC;PEG;Ammonio methacrylate copolymer;Triethyl citrate;Talc;Colloidal silicon dioxide;Titanium oxide;GelatinCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture immediately without chewing.Rhodes Pharmaceuticals1955Rytary™/carbidopa and levodopaTreatment of Parkinson\'s disease, post-encephalitic parkinsonism, and parkinsonism caused by carbon monoxide or manganese intoxication23.75/95, 36.25/145, 48.75/195, and 61.25/245 mg carbidopa/mg levodopa\
Store at 25 °C and protect from light and moisture.MCC;Mannitol;Tartaric acid;Ethyl cellulose;HPMC;Sodium starch glycolate;SLS;Povidone;Talc;Methacrylic acid copolymer;Triethyl citrate;Croscarmellose sodium;Magnesium stearateCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture immediately.Impax Laboratories1975Gocovri™/\
amantadineTreatment of dyskinesia in patients with Parkinson\'s disease receiving levodopa-based therapy68.5 and 137 mg\
Store at 20 to 25 °C.Copovidone;EC;HPMC;Magnesium stearate;Medium chain triglycerides;MCC;Povidone;TalcCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture immediately without chewing.Adamas Pharmaceuticals1968Amrix^Ⓡ^/\
cyclobenzaprine hydrochlorideRelief of muscle spasm associated with acute, painful musculoskeletal conditions15 and 30 mg\
Store at 25 °C and protect from light.DEP;EC;Gelatin;Opadry Clear YS-1-7006 Sugar spheres (20--25 mesh);Titanium dioxideCarefully open the capsule and sprinkle the contents on applesauce.\
Do not use other foods.\
Do not chew the granules.Teva Pharmaceuticals1977Verelan^Ⓡ^/\
verapamil hydrochlorideTreatment of hypertension120, 180, 240, and 360 mg\
Store at 20 to 25 °C and protect from light and moisture.Fumaric acid;Talc;Sugar spheres;Povidone;Shellac;Gelatin;FD&C red \#40;Yellow iron oxide;Titanium dioxide;Methylparaben;Propylparaben;SD;SLSCarefully open the capsule and sprinkle the contents on applesauce that is not warm.\
Ingest the mixture immediately without chewing.Recro Gainesville1991Kapspargo™ Sprinkle/\
metoprolol succinateTreatment of hypertension, angina pectoris, and heart failure25, 50, 100, and 200 mg\
Store at 20 to 25 °C.EC;HPMC;PEG400;PEG6000;Sugar spheres;Talc;Triethyl citrateCarefully open the capsule and sprinkle the contents on applesauce, pudding, or yogurt.\
Ingest the mixture within 60 min.Sun Pharmaceutical1992Coreg^Ⓡ^ CR/\
carvedilol phosphateTreatment of mild to chronic heart failure, left ventricular dysfunction following myocardial infarction, and hypertension10, 20, 40, and 80 mg\
Store at 25 °C and protect from light.Crospovidone;Hydrogenated castor oil;Hydrogenated vegetable oil;Magnesium stearate;Methacrylic acid copolymer;MCC;PovidoneCarefully open the capsule and sprinkle the contents on applesauce that is not warm.GlaxoSmithKline1995Qudexy^Ⓡ^ XR/\
topiramateTreatment of seizures associated with epilepsy or Lennox-Gastaut syndrome and prevention of migraine25, 50, 100, 150, and 200 mg\
Store at 20 to 25 °C and protect from moisture.MCC;HPMC 2910;EC;DEP;Titanium dioxide;Black iron oxide;Red iron oxide;Yellow iron oxideCarefully open the capsule and sprinkle the contents on soft food.\
Ingest the mixture immediately without chewing or crushing.Upsher-Smith Laboratories1996Effexor XR^Ⓡ^/\
venlafaxineTreatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder37.5, 75, and 150 mg\
Store at 20 to 25 °C.Cellulose;EC;Gelatin;HPMC;Iron oxide;Titanium dioxideCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture immediately without chewing.Wyeth1997Klor-Con^Ⓡ^ Sprinkle/potassium chlorideTreatment or prevention of hypokalemia600 and 750 mg\
Store at 20 to 25 °C and protect from light and moisture.EC;Talc;Gelatin;Titanium dioxideCarefully open the capsule and sprinkle the contents on soft foods, such as applesauce or pudding.\
Ingest the mixture immediately without chewing.Upsher-Smith Laboratories1998Adderall XR^Ⓡ^/dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfateTreatment of ADHD5, 10, 15, 20, 25, and 30 mg\
Store at 25 °C.HPMC;Methacrylic acid copolymer;Opadry beige;Sugar spheres;Talc;Triethyl citrateCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture immediately without chewing.Shire2001Namenda XR™/memantine hydrochlorideTreatment of moderate to severe dementia of the Alzheimer\'s type7, 14, 21, and 28 mg\
Store at 25 °C.Sugar spheres;PVP;HPMC;Talc;PEG;EC;Ammonium hydroxide;Oleic acid;Medium chain triglyceridesCarefully open the capsule and sprinkle the contents on applesauce.Forest2003Embeda™/morphine sulfate and naltrexone hydrochlorideManagement of moderate to severe pain20/0.8, 30/1.2, 50/2, 60/2.4, 80/3.2, and 100/4 mg morphine sulfate/mg naltrexone hydrochloride\
Store at 25 °C and protect from light.Talc;Ammonio methacrylate copolymer;Sugar spheres;EC;Sodium chloride;PEG;HPC;DBS;Methacrylic acid copolymer DEP;Magnesium stearate;SLS;Ascorbic acidCarefully open the capsule and sprinkle the contents on applesauce.\
Do not use other foods.\
Do not chew the granules.Alpharma Pharmaceuticals2009Namzaric^Ⓡ^/memantine hydrochloride and donepezil hydrochlorideTreatment of moderate to severe dementia of the Alzheimer\'s type14/10 and 28/10 mg memantine hydrochloride/ mg donepezil hydrochloride\
Store at 25 °C and protect from light.Sugar spheres;Povidone;Talc;HPMC;PEG;EC;Oleic acid;Medium chain triglycerides;Lactose monohydrate;MCC;Corn starch;Colloidal silicon dioxide;Magnesium stearateCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture without chewing.Allergan2014Table 6Commercially available sprinkle products -- DR capsules.Table 6Brand/Generic namesIndicationStrength/StorageExcipientsManipulationCompanyInitial US approvalDepakote^Ⓡ^ Sprinkle Capsules/divalproex sodiumTreatment of epilepsy125 mg\
Store below 25 °C.Cellulosic polymers\
Iron oxide\
Magnesium stearate\
Silica gel\
Titanium dioxide\
Triethyl citrateCarefully open the capsule and sprinkle the contents on soft foods, such as applesauce or pudding.\
Ingest the mixture immediately without chewing.AbbVie1989Esomeprazole Strontium Delayed-Release Capsules/esomeprazole strontiumTreatment of GERD, gastric ulcer, and pathological hypersecretory conditions, and eradication of *Helicobacter pylori*.49.3 mg\
Store at 20 to 25 °C.Calcium carbonate\
HPMC\
Methacrylic acid copolymer\
Mono and diglycerides\
Polysorbate 80\
Sugar spheres\
Talc\
Triethyl citrateThe capsule contents should only be sprinkled on applesauce, as the other soft foods has not been tested.\
Ingest the mixture immediately without chewing.R2 Pharma1989Nexium^Ⓡ^/esomeprazole magnesiumTreatment of GERD and pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome), and eradication of *Helicobacter pylori*.20 and 40 mg\
Store at 25 °C.Glyceryl monostearate 40--55\
HPC\
HPMC\
Magnesium stearate\
MCC\
Polysorbate 80\
Sugar spheres\
Talc\
Triethyl citrateCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture immediately without chewing.AstraZeneca1989Procysbi^Ⓡ^/cysteamine bitartrateTreatment of nephropathic cystinosis25 and 75 mg\
Store at 2 to 8 °C and at 20 to 25 °C before and after dispensing, respectively, and protect from light and moisture.MCC\
Eudragit L 30 d-55\
HPMC\
Talc\
Triethyl citrate\
SLSCarefully open the capsule and sprinkle the contents on applesauce, berry jelly, or fruit juice.\
Do not use grapefruit juice.\
Ingest the mixture within 30 min without chewing.Horizon1994Dexilant^Ⓡ^/dexlansoprazoleTreatment of erosive esophagitis and GERD30 and 60 mg\
Store at 20 to 25 °C.Sugar spheres\
Magnesium carbonate\
Sucrose\
L-HPC\
Titanium dioxide\
HPC\
HPMC 2910\
Talc\
Methacrylic acid copolymers\
PEG 8000\
Triethyl citrate\
Polysorbate 80\
Colloidal silicon dioxideCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture immediately without chewing.Takeda1995Prevacid^Ⓡ^/lansoprazoleTreatment of gastric/duodenal ulcer, GERD, erosive esophagitis, and pathological hypersecretory conditions, and eradication of *Helicobacter pylori*.15 and 30 mg\
Store at 25 °C.HPC\
L-HPC\
Colloidal silicon dioxide\
Magnesium carbonate\
Methacrylic acid copolymer\
Starch\
Talc\
Sugar sphere\
Sucrose\
PEG\
Polysorbate 80\
Titanium dioxideCarefully open the capsule and sprinkle the contents on applesauce, Ensure, pudding, cottage cheese, yogurt, strained pears, apple juice, orange juice, or tomato juice.\
Ingest the mixture immediately.Takeda1995Aciphex^Ⓡ^ sprinkle™/rabeprazole sodiumTreatment of GERD5 and 10 mg\
Store at 25 °C and protect from moisture.Colloidal silicon dioxide\
Diacetylated monoglycerides\
EC\
HPC\
HPMCP\
Magnesium oxide\
Magnesium stearate\
Mannitol\
Talc\
Titanium dioxide\
Carrageenan\
Potassium chlorideCarefully open the capsule and sprinkle the contents on applesauce, fruit- or vegetable-based baby food, yogurt, infant formula, apple juice, or pediatric electrolyte solution.\
Ingest the mixture within 15 min without chewing.Cerecor1999Creon^Ⓡ^/pancrelipaseTreatment of exocrine pancreatic insufficiency3/9.5/15, 6/19/30, 12/38/60, 24/76/120, and 36/114/180 × 10^3^ USP units of lipase/protease/amylase\
Store below 25 °C and protect from moisture.Cetyl alcohol\
Dimethicone\
HPMCP\
PEG\
Triethyl citrateFor infants, administer the capsule contents before breast-feeding. Contents should not be mixed directly into infant formula or breast milk.\
For children and adults, carefully open the capsule and sprinkle the contents on acidic soft food with a pH of 4.5 or less, such as applesauce, at room temperature.\
Ingest the mixture immediately without chewing.\
Ensure that no drug is retained in the mouth.AbbVie2009Zenpep^Ⓡ^/pancrelipaseTreatment of exocrine pancreatic insufficiency3/10/14, 5/17/24, 10/32/42, 15/47/63, 20/63/84, 25/79/105, and 40/126/168 × 10^3^ USP units of lipase/protease\
Store at 25 °C and protect from moisture.Colloidal silicon dioxide\
Croscarmellose sodium\
Hydrogenated castor oil HPMCP\
Magnesium stearate\
MCC\
Talc\
Triethyl citrateFor infants, administer the capsule contents before breast-feeding. Contents should not be mixed directly into infant formula or breast milk.\
For children and adults, carefully open the capsule and sprinkle the contents on acidic soft food with a pH of 4.5 or less, such as applesauce and commercially available preparations of bananas or pears.\
Ingest the mixture immediately without chewing.\
Ensure that no drug is retained in the mouth.Forest2009Pancreaze^Ⓡ^/pancrelipaseTreatment of exocrine pancreatic insufficiency2.6/6.2/10.85, 4.2/14.2/24.6, 10.5/35.5/61.5, 16.8/56.8/98.4 and 21/54.7/83.9 × 10^3^ USP units of lipase/protease/amylase\
Store below 25 °C in the original container and protect from moisture.Cellulose;\
Colloidal anhydrous silica\
Crospovidone\
Magnesium stearate\
Methacrylic acid-ethyl acrylate copolymer\
Montan glycol wax\
Simethicone emulsion\
Talc\
Triethyl citrateFor infants, administer the capsule contents before breast-feeding. Contents should not be mixed directly into infant formula or breast milk as this may compromise efficacy.\
For children and adults, carefully open the capsule and sprinkle the contents on acidic soft food with a pH of 4.5 or less, such as applesauce, at room temperature.\
Ingest the mixture immediately without chewing.\
Ensure that no drug is retained in the mouth.Vivus2010Pertzye^Ⓡ^/pancrelipaseTreatment of exocrine pancreatic insufficiency4/14.375/15.125, 8/28.75/30.25, and 16/57.5/60.5 × 10^3^ USP units of lipase/protease\
Store at 20 to 25 °C and protect from moisture.Sodium bicarbonate\
Sodium carbonate\
Cellulose acetate phthalate\
Sodium starch glycolate\
DEP\
Ursodiol\
PVP\
TalcFor infants, administer the capsule contents before breast-feeding. Contents should not be mixed directly into infant formula or breast milk as this may diminish efficacy.\
For children and adults, carefully open the capsule and sprinkle the contents on acidic soft food with a pH of 4.5 or less, such as applesauce, at room temperature.\
Ingest the mixture immediately without chewing.\
Ensure that no drug is retained in the mouth.Digestive Care2012Ultresa™/pancrelipaseTreatment of exocrine pancreatic insufficiency4/8/8, 13.8/27.6/27.6, 20.7/41.4/41.4, and 23/46/46 × 10^3^ USP units of lipase/protease/amylase\
Store at 20 to 25 °C and protect from moisture.Colloidal silicon dioxide\
Croscarmellose sodium\
Hydrogenated castor oil HPMCP\
Magnesium stearate\
MCC\
Talc\
Triethyl citrateFor infants, administer the capsule contents before breast-feeding. Contents should not be mixed directly into infant formula or breast milk as this may reduce efficacy.\
For children and adults, carefully open the capsule and sprinkle the contents on acidic soft food with a pH of 4.5 or less, such as applesauce, at room temperature.\
Ingest the mixture immediately without chewing.\
Ensure that no drug is retained in the mouth.Forest2012Table 7Commercially available sprinkle products -- MDDS.Table 7Brand/Generic NamesIndicationStrength/StorageExcipientsManipulationCompanyInitial US ApprovalJornay PM/methylphenidate hydrochlorideTreatment of ADHD20, 40, 60, 80, and 100 mg\
Store at 20 to 25 °C and protect from moisture.DBS;EC;HPC;HPMC;Magnesium stearate;Methacrylic acid copolymer;MCC;Mono and diglycerides;Polysorbate 80;TalcCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture immediately.Ironshore Pharmaceuticals1955Equetro^Ⓡ^/carbamazepineTreatment of acute manic or mixed episodes associated with bipolar I disorder, pain associated with trigeminal neuralgia, and epilepsy100, 200, and 300 mg\
Store at 25 °C and protect from light and moisture.Citric acid;Colloidal silicon dioxide;Lactose monohydrate;MCC;PEG;Povidone;SLS;Talc;Triethyl citrateCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture without chewing.Validus Pharmaceuticals1968Carbatrol^Ⓡ^/carbamazepineTreatment of pain associated with trigeminal neuralgia and epilepsy100, 200, and 300 mg\
Store at 25 °C and protect from light and moisture.Citric acid;Colloidal silicon dioxide;Lactose monohydrate;MCC;PEG;Povidone;SLS;Talc;Triethyl citrateCarefully open the capsule and sprinkle the contents on applesauce.Shire1998Verelan^Ⓡ^ PM/verapamil hydrochlorideManagement of essential hypertension100, 200, and 300 mg\
Store at 25 °C and protect from moisture.Fumaric acid;Povidone;Shellac;SD;SLS;Starch;Sugar spheres;Talc;Titanium dioxideCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture immediately without chewing.Recro Gainesville1998Metadate CD^Ⓡ^/methylphenidate hydrochlorideTreatment of ADHD10, 20, 30, 40 and 60 mg\
Store at 15 to 30 °C and protect from moisture.Sugar spheres;Povidone;HPMC;PEG;EC;DBS;Gelatin;Titanium dioxideCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture immediately without chewing.UCB2001Mydayis^Ⓡ^/dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate monohydrateTreatment of ADHD12.5, 25, 37.5, and 50 mg\
Store at 20 to 25 °CEC;HPMC;Methacrylic acid copolymer;Methyl acrylate;Methyl methacrylate;Opadry beige;Sugar spheres;Talc;Triethyl citrateCarefully open the capsule and sprinkle the contents on applesauce.Shire2001Ritalin LA^Ⓡ^/methylphenidate hydrochlorideTreatment of ADHD10, 20, 30, and 40 mg\
Store at 25 °C.Ammonio methacrylate copolymer;Black iron oxide (10 and 40 mg strengths);Gelatin;Methacrylic acid copolymer;PEG;Red iron oxide (10 and 40 mg strengths);Sugar spheres;Talc;Titanium dioxide;Triethyl citrate;Yellow iron oxide (10, 30, and 40 mg strengths)Carefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture immediately without chewing.Novartis2002Focalin XR^Ⓡ^/dexmethylphenidate hydrochlorideTreatment of ADHD5, 10, 15, 20, 25, 30, 35, and 40 mg\
Store at 25 °C.Ammonio methacrylate copolymer;FD&C Blue \#2 (5, 15, 25, 35, and 40 mg strengths); Yellow iron oxide (10, 15, 30, 35, and 40 mg strengths);Gelatin;Ink Tan SW-8010;Methacrylic acid copolymer;PEG;Sugar spheres\
Talc;Titanium dioxide;Triethyl citrateCarefully open the capsule and sprinkle the contents on applesauce.\
Ingest the mixture immediately.Novartis2005

2. Types of sprinkle formulations {#sec0002}
=================================

2.1. Method of collecting information on sprinkle drug products {#sec0003}
---------------------------------------------------------------

Sixty-five New Drug Applications (NDAs) for sprinkle drug products were found in the FDA database (<https://www.accessdata.fda.gov/scripts/cder/daf/>; last accessed October 2018). The product list was compiled based on the labeling information of each product ([Table 1](#tbl0001){ref-type="table"}, [Table 2](#tbl0002){ref-type="table"}, [Table 3](#tbl0003){ref-type="table"}, [Table 4](#tbl0004){ref-type="table"}, [Table 5](#tbl0005){ref-type="table"}, [Table 6](#tbl0006){ref-type="table"}, [Table 7](#tbl0007){ref-type="table"}). Unless otherwise noted, the other information including generic name, drug substance, pharmaceutical ingredients, storage condition, and administration method was also adapted from each product labeling.

2.2. Tablets {#sec0004}
------------

The labeling of tablet formulations usually carries a warning that the product must not be crushed [@bib0010]. However, there are more than nine crushable tablet products commercially available. The administration of this sprinkle tablet is performed by carefully crushing the tablet and immediately sprinkling the fragments on soft food so that the patients can easily swallow them with food.

Doryx^Ⓡ^ (doxycycline hyclate; Mylan) is used to treat or prevent infections that are caused by bacteria [@bib0011]. Doryx^Ⓡ^ tablets contain coated pellets of doxycycline hyclate in a DR formulation. The tablet of 50/200 mg dose contains lactose, microcrystalline cellulose (MCC), povidone, starch wheat, magnesium stearate, and cellulosic polymer coating. After crushed, the obtained Doryx^Ⓡ^ pellets can be sprinkled on applesauce and administered. The extent of absorption of doxycycline does not change with concomitant water, but the absorption rate increases slightly.

Jadenu^Ⓡ^ (deferasirox; Novartis) is an iron chelator agent indicated for the treatment of chronic iron overload caused by blood transfusions. Jadenu^Ⓡ^ includes 90, 180, and 360 mg deferasirox. Inactive ingredients include MCC, crospovidone, povidone K30, magnesium stearate, colloidal silicon dioxide and poloxamer 188. The instruction for manipulation is to carefully crush the tablet and immediately sprinkle the contents on applesauce. Commercial grinders with serrated surfaces should be avoided when crushing the 90 mg tablet. Sprinkled tablets should be consumed immediately and completely.

Xarelto^Ⓡ^ (rivaroxaban; Janssen) is an anticoagulant or blood-thinner to reduce the risk of pulmonary embolism, deep vein thrombosis, and stroke systemic embolism. It is available in 10, 15, and 20 mg tablets, and contains croscarmellose sodium, hypromellose (HPMC), lactose monohydrate, magnesium stearate, MCC, and sodium lauryl sulfate (SLS). Crushed Xarelto^Ⓡ^ is stable in applesauce and water for up to 4 h. A crushed Xarelto^Ⓡ^ tablet showed a comparable relative bioavailability compared with an intact tablet [@bib0012].

Savaysa^Ⓡ^ (edoxaban; Daiichi Sankyo) is a factor Xa inhibitor to reduce the risk of systemic embolism and stroke in patients with nonvalvular atrial fibrillation. The product comes in 15, 30, and 60 mg strengths, and contains mannitol, pregelatinized starch, crospovidone, hydroxypropyl cellulose (HPC), magnesium stearate, talc, and carnauba wax. The total systemic exposure of edoxaban is not affected by food. Administration of a crushed tablet mixed with soft food or suspended in water and given *via* a nasogastric tube showed similar absorption with the administration of an intact tablet.

Emflaza™ (deflazacort; PTC Therapeutics) is a corticosteroid used to treat Duchenne muscular dystrophy. It is available in 6, 18, 30, and 36 mg tablets, and contains colloidal silicon dioxide, lactose monohydrate, magnesium stearate, and pre-gelatinized corn starch. Crushing and sprinkling of Emflaza™ on applesauce did not influence the bioavailability of deflazacort.

2.3. Powders {#sec0005}
------------

Powder is much easier to administer with food or drink to elderly and pediatric patients compared with tablets or capsules. The powder formulations usually have fine bead-like morphology. The powder is typically 0.1 to 10 µm in size [@bib0013]. Commercially, there are more than four products of sprinkle powder.

Viread^Ⓡ^ (tenofovir disoproxil fumarate; Gilead Sciences) is a nucleotide analog that acts as reverse transcriptase inhibitor for human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus. In a bioequivalence study conducted under non-fasting conditions, the average maximum plasma concentration (C~max~) of tenofovir was 26.9% lower for the oral powder compared with the tablet formulation. According to the FDA review document, this difference can be attributed to the taste-masking technology used in Viread^Ⓡ^ [@bib0014]. However, the mean values of total area under the plasma concentration-time curve (AUC) of tenofovir were similar between the powder and the tablet.

Fosrenol^Ⓡ^ (lanthanum carbonate; Shire) is a phosphate binder for reducing serum phosphate level in patients with the end-stage renal disease. This product is available in 750 or 1000 mg strength and contains colloidal silicon dioxide, dextrates, and magnesium stearate as excipients. It is recommended to sprinkle Fosrenol^Ⓡ^ on a small quantity of applesauce or other similar food, rather than to mix with liquid vehicles due to its poor solubility.

Kuvan^Ⓡ^ (sapropterin dihydrochloride; BioMarin Pharmaceutical) can decrease blood phenylalanine levels. Kuvan^Ⓡ^ is available in unit capacity packets of 100 or 500 mg of sapropterin dihydrochloride. Each unit dose packet contains ascorbic acid, [d]{.smallcaps}-mannitol, potassium citrate, and sucralose. For infants weighing less than 10 kg, dissolve powder in 5 ml of water or apple juice. Some of this solution can be administered orally via a syringe. Kuvan^Ⓡ^ powder is bioequivalent to the same dose of Kuvan^Ⓡ^ tablet. Before administration, the packet content needs to be dissolved in 120--240 ml of water or apple juice; or sprinkled on a small amount of soft food such as applesauce or pudding. However, administration with high-fat/high-calorie meal caused 1.84- and 1.87-fold increase in the mean C~max~ and AUC values of sapropterin, respectively, with extensive individual variability.

2.4. Granules {#sec0006}
-------------

Granules are large and free-flowing particles, which are commonly prepared by the agglomeration of powder. There are three types of granulations as dry granulation, wet granulation and fluid bed granulation. Dry granulation is made by crushing large masses of powder mixture into small pieces, and wet granules are made by adding a liquid binder or adhesive. Fluid bed granulation is made by spraying a granulating solution onto the particles [@bib0013]. Their size ranges from 0.85 mm (sieve No. 20) to 4.75 mm (sieve No. 4). The shape of granules is generally irregular [@bib0013]. There are more than seven sprinkle granule products commercially available, which can be sprinkled on liquid or soft foods and swallowed without chewing.

Singulair^Ⓡ^ (montelukast sodium; Merck) is a leukotriene receptor antagonist for prophylaxis and chronic treatment of asthma, acute prevention of exercise-induced bronchoconstriction, and alleviation of allergic rhinitis. The product is available in 4 mg dose, and the inactive ingredients include mannitol, HPC, and magnesium stearate. Singulair^Ⓡ^ granules can be administered by dissolving in a teaspoonful of baby formula or breast milk or mixing with a spoonful of soft food such as applesauce, carrots, rice or ice cream.

Jadenu^Ⓡ^ Sprinkle (deferasirox; Novartis) is used for chronic iron overload caused by blood transfusion. Jadenu^Ⓡ^ Sprinkle granules contain 90, 180, and 360 mg deferasirox. MCC, povidone K30, magnesium stearate, colloidal silicon dioxide, and poloxamer 188 are included as excipients. The bioavailability (as AUC) of granules was 52% higher than tablets, and the mean C~max~ increased by 34% in the fasted state, although the results were not clinically relevant. When sprinkle granules were taken with low-calorie food (approximately 450 calories with a fat content around 30% of total calories), AUC and C~max~ were similar to those under fasting condition. However, when administered with high-calorie food (approximately 1000 calories with a fat content higher than 50% of total calories), AUC increased by 18% without changes in C~max~.

Xuriden^Ⓡ^ (uridine triacetate; Wellstat Therapeutics Co.) is a pyrimidine analog for the therapy of hereditary orotic aciduria. Xuriden^Ⓡ^ 2 g packet contains ethylcellulose (EC), HPMC, and polyethylene glycol (PEG) as inactive ingredients. The granules can be sprinkled on applesauce, pudding, or yogurt; or may be mixed with milk or infant formula. The food effect on uridine pharmacokinetics was negligible, showing no difference in total urinary exposure and range.

Solosec™ (secnidazole; Lupin) is a nitroimidazole antimicrobial for the treatment of bacterial vaginosis in adult women. Yellowish granules (4.8 g), which contain 2 g of secnidazole, are packed in a foil packet that is difficult for children to open. The other ingredients are ethyl acrylate-methyl methacrylate copolymer, PEG4000, povidone, sugar spheres, and talc. Solosec™ exhibited no significant difference in C~max~ and AUC values when administered under fasting conditions (mixed with applesauce) or with high-calorie foods. Administration of Solosec™ with pudding or yogurt showed no difference either.

2.5. Immediate-release capsules {#sec0007}
-------------------------------

Most oral formulations such as tablets, powder, granules, and capsules are designed to release the drug immediately after oral administration [@bib0015]. IR products generally provide fast absorption of the drug and consequent rapid onset of the pharmacokinetic effects. There are at least nine sprinkle IR capsule products available commercially. Sprinkle IR capsules should be opened carefully, and the contents sprinkled on soft foods need to be swallowed immediately without chewing.

Sustiva^Ⓡ^ (efavirenz; Bristol-Myers Squibb), a non-nucleoside reverse transcriptase inhibitor, is used in combination with other antiretroviral agents for the treatment of HIV-1 infection. Sustiva^Ⓡ^ contains 50 or 200 mg of efavirenz and lactose monohydrate, magnesium, stearate, SLS, and sodium starch glycolate as inactive ingredients. This product should be administered orally once daily on an empty stomach, preferably at bedtime. The AUC value of Sustiva^Ⓡ^ sprinkled on applesauce was bioequivalent to that of the intact Sustiva^Ⓡ^ capsule when administered in the fasted state.

Topamax^Ⓡ^ Sprinkle Capsules (topiramate; Janssen) are used for the treatment of epileptic convulsions and migraine in adults and children. Topamax^Ⓡ^ sprinkle capsules include 15 or 25 mg of topiramate-coated beads in a hard gelatin capsule. Cellulose acetate, gelatin, povidone, SLS, sorbitan monolaurate, sugar spheres, and titanium dioxide are added as excipients. Topamax^Ⓡ^ Sprinkle Capsules are bioequivalent to the immediate-release tablet. Food does not affect the bioavailability of topiramate.

Colazal™ (balsalazide disodium; Valeant Pharms) is a locally acting aminosalicylate to treat mild to active ulcerative colitis. The 750 mg capsules have colloidal silicon dioxide and magnesium stearate as inactive ingredients. The systemic absorption of Colazal™ exhibited high variability in C~max~ and AUC values when administered as sprinkles and intact capsules. However, its ingestion with high-fat meal markedly delayed the time to reach C~max~ (T~max~) compared with administration in the fasted state.

Tasigna^Ⓡ^ (nilotinib; Novartis) is a kinase inhibitor used to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. Tasigna^Ⓡ^ contains 150 or 200 mg nilotinib with colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, and poloxamer 188. Tasigna^Ⓡ^ sprinkled on applesauce and administered within 15 min is bioequivalent to the intact capsule.

Rapaflo^Ⓡ^ (silodosin; Allergan) was developed for the treatment of benign prostatic hyperplasia. Rapaflo^Ⓡ^ capsules include 4 or 8 mg of silodosin with [D]{.smallcaps}-mannitol, magnesium stearate, pre-gelatinized starch, and SLS. The bioequivalent AUC and C~max~ values were observed when the capsule was administrated intact or with the capsule content sprinkled on applesauce.

2.6. Extended-release capsules {#sec0008}
------------------------------

ER drug products can reduce the frequency of dosing more than two-fold compared with IR (conventional) products [@bib0015]. ER dosage forms are divided into two types: sustained-release (SR) and controlled-release (CR) types. SR type releases cargo molecules over a sustained period, but not at a constant rate, whereas CR type releases the drug at a nearly constant rate [@bib0016]. More than twenty products are listed as ER sprinkle capsules in the FDA database. The method of administration of ER capsules is the same as that of IR capsules.

Kadian^Ⓡ^ (morphine sulfate; Actavis) is an opioid agonist for the management of severe pain. Kadian^Ⓡ^ contains 10, 20, 30, 40, 50, 60, 70, 80, 100, 130, 150, or 200 mg of morphine sulfate with HPMC, EC, methacrylic acid copolymer, PEG, DEP, talc, corn starch, and sucrose. Capsule contents of Kadian^Ⓡ^ can be administered by sprinkling on applesauce, which is bioequivalent to the intact capsule.

Rytary™ (carbidopa and levodopa; Impax Laboratories) is indicated for the treatment of Parkinson\'s disease. Rytary™ comes in 23.75/95, 36.25/145, 48.75/195, and 61.25/245 mg strengths (carbidopa/levodopa). The inactive ingredients are MCC, mannitol, tartaric acid, ethyl cellulose, HPMC, sodium starch glycolate, SLS, povidone, talc, methacrylic acid copolymer, triethyl citrate, croscarmellose sodium, and magnesium stearate.

Gocovri™ (amantadine; Adamas Pharmaceuticals) is used to treat dyskinesia in patients with Parkinson\'s disease. Each amantadine capsule (68.5 or 137 mg dose) contains copovidone, EC, HPMC, magnesium stearate, medium chain triglyceride, MCC, povidone, and talc as excipients. Administration of Gocovri™ as sprinkles on applesauce exerted no significant effect on the plasma pharmacokinetics of amantadine compared with the intact capsule administration. In addition, concomitant high-calorie food also did not affect the amantadine pharmacokinetics.

Amrix^Ⓡ^ (cyclobenzaprine hydrochloride; Teva Pharmaceuticals) is a muscle relaxant to be used as an adjunct to rest and physical therapy. Amrix^Ⓡ^ comes in 15 and 30 mg capsules, and the inactive ingredients include diethyl phthalate(DEP), EC, gelatin, Opadry^Ⓡ^ Clear YS-1-7006, sugar spheres NF (20--25 mesh), and titanium dioxide. Bioequivalence of Amrix^Ⓡ^ capsules administered as sprinkles on applesauce compared with the intact capsule was proved.

Verelan^Ⓡ^ (verapamil hydrochloride; Recro Gainesville) is used for the management of essential hypertension. This product contains 100, 200, or 300 mg of verapamil hydrochloride and fumaric acid, povidone, shellac, SD, SLS, starch, sugar spheres, talc, and titanium dioxide as inactive ingredients. When Verelan^Ⓡ^ capsule was administered by sprinkling on applesauce, the rate and extent of verapamil absorption were bioequivalent to those of the intact capsule with the same dose.

Adderall XR^Ⓡ^ (dextroamphetamine sulfate; Shire) is used for the treatment of attention deficit hyperactivity disorder (ADHD). While the conventional Adderall tablets are designed for IR type drug release, Adderall XR^Ⓡ^ capsules, which contains two types of drug-containing beads, provide double-pulsed delivery of amphetamine. The inactive ingredients in 5, 10, and 15 mg Adderall XR^Ⓡ^ capsules include HPMC, methacrylic acid copolymer, Opadry^Ⓡ^ beige, sugar spheres, talc, and triethyl citrate. Adderall XR^Ⓡ^ capsules administered as an intact capsule and sprinkles on applesauce were bioequivalent in the fasted condition. Moreover, Adderall IR tablets (twice a day) can be replaced with the same dose of Adderall XR^Ⓡ^ capsules (once a day).

Namzaric^Ⓡ^ ER capsules (memantine hydrochloride and donepezil hydrochloride; Allergan) are indicated for the treatment of moderate to severe dementia of the Alzheimer type. Namzaric^Ⓡ^ contains 14/10 mg or 28/10 mg of memantine hydrochloride/donepezil hydrochloride in each capsule. The other components are sugar spheres, povidone, talc, HPMC, PEG, EC, oleic acid, medium chain triglycerides, lactose monohydrate, MCC, corn starch, colloidal silicon dioxide, and magnesium stearate. C~max~ and AUC values of Namzaric^Ⓡ^ in the fed and fasted conditions were similar. Moreover, no significant difference in the absorption of memantine hydrochloride was observed when the capsule was administrated intact or with its contents sprinkled on applesauce.

2.7. Delayed-release capsules {#sec0009}
-----------------------------

In general, DR dosage forms refer to enteric-coated formulations, of which drug release begins after a predetermined delay [@bib0013]. More than twelve products are listed as DR sprinkle capsules. The administration method of the DR capsule is the same as those of the IR and ER capsules. However, in most cases, DR and ER products are not interchangeable due to the difference in release pattern.

Depakote^Ⓡ^ sprinkle capsule (divalproex sodium; AbbVie) is used as monotherapy or adjuvant therapy for complex partial seizures of adult and pediatric patients (ten years of age and older) [@bib0017]. The coated beads of divalproex sodium are contained in a hard gelatin capsule. Cellulosic polymers, iron oxide, magnesium stearate, silica gel, titanium dioxide, and triethyl citrate are added as inactive ingredients. Depakote^Ⓡ^ sprinkle capsule should not be used as a substitute for Depakote^Ⓡ^ ER tablet, as these products have different pharmacokinetic properties.

Esomeprazole Strontium Delayed-Release Capsules (esomeprazole strontium; R2 Pharma) are used for gastroesophageal reflux disease (GERD), gastric and duodenal ulcer, and pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome) in adults. This product comes in 49.3 mg dose and contains calcium carbonate, HPMC, methacrylic acid copolymer, mono and diglycerides, polysorbate 80, sugar spheres, talc, and triethyl citrate. When administered after a high fat meal, AUC value was reduced by 52% compared with fasting condition.

Aciphex^Ⓡ^ Sprinkle™ (rabeprazole sodium; FSC Laboratories) is a proton-pump inhibitor (PPI) for GERD. This product contains granules of 5 or 10 mg of rabeprazole sodium in a hard hypromellose capsule. The inactive ingredients are colloidal silicon dioxide, diacetylated monoglycerides, EC, HPC, hypromellose phthalate (HPMCP), magnesium oxide, magnesium stearate, mannitol, talc, titanium dioxide, carrageenan, and potassium chloride. Aciphex^Ⓡ^ administered with high-fat meal exhibited reduced C~max~ and AUC (by 55% and 33%, respectively) as well as delayed median T~max~ (from 2.5 to 4.5 h) compared with that with applesauce under fasted condition. The type of soft food (e.g., applesauce, yogurt and liquid infant formula) did not significantly change T~max~, C~max~, and AUC of rabeprazole.

2.8. Multiparticulate drug delivery system (MDDS) {#sec0010}
-------------------------------------------------

The MDDS oral dosage form consists of small individual subunits (e.g., beads or microencapsulated drugs) that exhibit different properties [@bib0018]. These subunits can be compressed into a tablet or packed into a capsule [@bib0019]. Most of the MDDS sprinkle products are designed based on the spheroidal oral drug absorption system (SODAS^Ⓡ^) or chronotherapeutic oral drug absorption system (CODAS^Ⓡ^) technologies.

Metadate CD^Ⓡ^ (methylphenidate hydrochloride; UCB) is a central nervous system stimulant for the treatment of ADHD. Metadate CD^Ⓡ^ has a biphasic release pattern, which is attributed from the IR (30% of dose) and ER (70% of dose) beads included in the capsule. Metadate CD^Ⓡ^ contains 10, 20, 30, 40, 50 or 60 mg of methylphenidate hydrochloride. The other components are sugar spheres, povidone, HPMC, PEG, EC aqueous dispersion, dibutyl sebacate (DBS), gelatin, and titanium dioxide. Metadate CD^Ⓡ^ administered as sprinkles on applesauce showed bioequivalent systemic exposure (as C~max~ and AUC) of methylphenidate compared with the intact capsule.

Ritalin LA^Ⓡ^ (methylphenidate; Novartis) and Focalin™ XR (dexmethylphenidate; Novartis) are also used to treat ADHD. Ritalin LA^Ⓡ^ and Focalin™ XR are designed based on SODAS^Ⓡ^ technology, with which uniform spherical beads of approximately 1 to 2 mm in diameter can be produced. The schematic illustration of SODAS^Ⓡ^ is shown in [Fig. 3](#fig0003){ref-type="fig"}. The spherical bead has a multilayered structure of a drug/excipients core and release-controlling polymer coatings [@bib0020], [@bib0021]. The polymers in the coating layers can be water soluble, insoluble, or even pH-responsive. Their physicochemical properties directly affect the release pattern of the final product [@bib0002]. Additionally, by compounding beads with different coatings, a customized drug-release profile can be achieved, which makes SODAS^Ⓡ^ a versatile oral drug delivery system [@bib0002].Fig. 3Schematic illustration of SODAS^Ⓡ^ technology. The spherical bead has a multilayered structure, of which the drug-containing core is coated with the layers of release-controlling polymers.Fig 3

Verelan^Ⓡ^ PM (verapamil hydrochloride; Schwarz Pharma) is used for the management of essential hypertension. Verelan^Ⓡ^ PM administered at bedtime shows a 4 to 5 h of delay in drug release. This product contains DR beads of CODAS^Ⓡ^, of which release-controlling polymer layer consists of both water-soluble and insoluble polymers. When contacted with water in the gastrointestinal tract, the water-soluble polymer in the coating gradually dissolves forming drug-releasing pores. The water-insoluble polymer acts as a barrier to control the release of the drug [@bib0022]. The release rate of Verelan^Ⓡ^ PM is independent of pH and concomitant food. Moreover, Verelan^Ⓡ^ PM administered as sprinkles on applesauce was bioequivalent to the intact capsule.

3. FDA guidance of sprinkle formulations {#sec0011}
========================================

A practical guidance that contains assessment criteria for manufacturing and quality control of sprinkle formulations has been needed. The FDA guidance on tablet scoring is related to this issue to a certain degree [@bib0023]. (1) The split tablet portion should not have a lower amount of drug than the minimum dose indicated on the approved labeling. (2) Modified-release products, of which drug release can be changed by splitting, should not be pre-scored. (3) The split tablet should be stable for 90 d under ambient condition. (4) The split tablet portions should meet the same criteria of finished-product testing as for a whole-tablet product of equivalent strength. However, this information is not directly applicable to sprinkle dosage forms.

In May 2012, the US FDA released a brief guideline on the products labeled for sprinkle, where the following three recommendations are listed [@bib0024]. The first is the maximum bead size of sprinkle drug products. The agency recommends a target bead size up to 2.5 mm with less than 10% variation and a maximum size of 2.8 mm to avoid inadvertent chewing. The unintentional chewing of beads may compromise the safety and efficacy of the loaded drug. For example, a burst or an early release of the drug may occur for the ER or DR beads, respectively, and the unpleasant taste of released drug may lead to poor compliance with the oral administration. Indeed, the labeling of most sprinkle beads states that the contents should not be crushed, chewed, split, or dissolved. The second topic of the guidance is the administration of the sprinkle products *via* the enteral feeding tube. According to these recommendations, the sprinkle drug products need to be delivered through an enteral feeding tube without loss of dose, crushing of beads, and tube occlusions. Also, the manufacturer should display special instructions on the product labeling regarding the information on this alternative delivery method. The third part of guidance contains the recommendations related to the bioequivalence and bioavailability studies. For the labeling to state that the drug product can be sprinkled, the information on the bioavailability or bioequivalence of the sprinkled formulation versus its intact form (for new drug applications, NDAs) or reference listed drug (for abbreviated new drug applications, ANDAs) should be included, respectively. Regarding the IR sprinkle products, the bioequivalence study is not necessary because their pharmacokinetic properties are expected to be similar compared with the IR product of reference listed drug.

Recently in July 2018, the US FDA released a draft guidance on the use of liquids and/or soft foods as vehicles for drug administration [@bib0025]. This article encompasses not only general considerations for soft food vehicles but also methodologies for assessing the impact of the vehicles on the drug product quality. The general considerations and recommendations part focuses on the compatibility and suitability for selecting soft foods, possible impacts of vehicles on the drug product, and patient adherence and acceptance in terms of palatability and swallowability. According to this part, the compatibility of commonly used soft foods with sprinkle formulations should be informed to ensure the efficacy and safety. Moreover, the product labeling needs to contain more than one example of soft food, because the limited types of food are inconvenient for patients with allergy or intolerance.

When evaluating the compatibility and suitability, not only the properties of drug substance or drug product but also those of foods, such as acidity and drug-binding/chelating characteristics, should be taken into account. Approximate pH ranges of commonly used soft foods and liquids are provided in this guidance ([Fig. 4](#fig0004){ref-type="fig"}). In addition, the age of the target population needs to be considered when selecting the flavor, texture, and mouthfeel of the food vehicles, as the age-related responses to these properties are different. For example, some vehicles with grainy texture may cause inadvertent chewing in young patients, and soft food vehicles are discouraged for infants who are able to ingest only the liquid foods.Fig. 4Approximate pH ranges of commonly used soft foods and liquids.(Adapted from Appendix A of Ref. [@bib0025].Fig 4

The guideline also provides methods for handling and dosing the mixture of the drug product and soft foods. The *in vitro* methods recommended for assessing impact of a vehicle on product quality attributes part presents a standardized methodology for evaluating the integrity and dose uniformity of drug products as well as the potency and stability of drug substance in the soft food vehicles. Moreover, this part provides general recommendations for dissolution testing of the mixture of the drug product and soft food.

4. Conclusions {#sec0012}
==============

Sprinkle formulations can improve compliance of patients with dysphagia. Indeed, more than 75% and 93% of children preferred sprinkle dosage form to syrup and oral drops, respectively [@bib0026], [@bib0027]. This preference spurred the growth of sprinkle products since the early 1990s as can be seen in [Fig. 1](#fig0001){ref-type="fig"}. However, the product number is still small; there have been only sixty-five NDA approvals. The limited kinds of sprinkle products compromise their flexibility and convenience of administration. In the complex medication regimen where both sprinkle and other dosage forms are mixed, patients would experience inconvenience due to the difference in administration methods. Considering this unmet need and the market trend, it is expected that more and more sprinkle products will be launched in the future. Nonetheless, this promising dosage form does not have comprehensive guidance for industry. Compilation and reinforcement of scattered information regarding sprinkle formulations in various regulatory documents would further accelerate their development and consequently provide higher therapeutic benefit for patients.
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